Kingsbarn Private Equity is focused on supporting buyouts in the lower middle market that are being led by management teams and independent sponsors. Our goal is to help support more successful ownership transitions by providing the hard-to-find equity required to meet the selling owners needs. With so many opportunities available to us, we are able to be very selective in the investments we make, enabling us to provide exceptional returns for our investors.
Larger businesses (greater than $5M EBITDA) typically trade at higher multiples which reduces the return profile to investors.
Acquisition multiples for companies under $5mm EBITDA are much lower, providing multiple arbitrage opportunity when EBITDA growth is achieved.
This creates a form of double return for investors - increase in profits and higher exit multiple - significantly increasing the IRR.
Easily implemented systems and processes that immediately create unrealized value in a small business.
Acquisition multiples for companies under $5mm EBITDA are much lower, providing multiple arbitrage opportunity when EBITDA growth is achieved.
This creates a form of double return for investors - increase in profits and higher exit multiple - significantly increasing the IRR.
Kingsbarn Private Equity launched in 2022 and closed its first investment in June with a $5.2M preferred equity investment in OMS Group, LLC. Founded in 1998, OMS Group is a precision manufacturer of custom designed motors, gears and other industrial applications that has been in business since 1998. They have a powersports division that primarily focuses on customized starter systems, but also has the capabilities to provide any application for motors, gears, and power electronics for their customers. They also have an engineered products division that operates as a contract manufacturer for end users requiring a high degree of precision for mechanical assemblies.
Advanced Radiotherapy Technologies ("ART") develops turnkey, freestanding radiotherapy centers for the use of physician practices and hospitals. ART has combined decades of experience in the development of superior radiotherapy centers to provide our clinical partners the best cancer care solutions for their patients.
ART's centers feature state-of-the-art radiotherapy equipment, such as, but not limited to, the RefleXion X-1, SOMATOM® go. platform, Varian Edge, and Somatom go.Pro. Our delivery includes financing, design, engineering, construction, equipment installation and clinical acceptance leading to first patient treatment. ART is currently seeking qualified clinical partners to integrate our cancer centers into their existing cancer care services.
ART is a joint venture formed by Integrated Proton Solutions ("IPS") and Kingsbarn Realty Capital ("KB").